Virus kills breast cancer cells in laboratory

A nondisease-causing virus kills human breast cancer cells in the laboratory, creating opportunities for potential new cancer therapies, according to Penn State College of Medicine researchers who tested the virus on three different breast cancer types that represent the multiple stages of breast cancer development.

Read more

Another step toward resisting breast cancer

Medical researchers at the University of Leeds have come a step closer to understanding how to stop breast cancers from coming back.

Their findings, published in the International Journal of Cancer, suggest that some novel drugs that are being developed to tackle other cancers should be considered as a future treatment for breast cancer too.

Read more

Gene therapy kills breast cancer stem cells, boosts chemotherapy

Gene therapy delivered directly to a particularly stubborn type of breast cancer cell causes the cells to self-destruct, lowers chance of recurrence and helps increase the effectiveness of some types of chemotherapy, researchers at The University of Texas MD Anderson Cancer Center reported in the Sept. 13 edition of Cancer Cell.

Read more

Research aims to starve breast cancer cells

The most common breast cancer uses the most efficient, powerful food delivery system known in human cells and blocking that system kills it, researchers report.

This method of starving cancer cells could provide new options for patients, particularly those resistant to standard therapies such as tamoxifen, Georgia Health Sciences University researchers said.

Read more

Mayo Clinic receives FDA approval for ovarian and breast cancer vaccines

ROCHESTER, Minn. — Mayo Clinic has received investigational new drug approval (http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/InvestigationalNewDrugINDorDeviceExemptionIDEProcess/default.htm) from the Food and Drug Administration (http://www.fda.gov/) for two new cancer vaccines that mobilize the body’s defense mechanisms to destroy malignant cells. The vaccines are among the first aimed at preventing cancer recurrence. The approval clears the way for Phase I clinical trials with women treated for ovarian or breast cancer.

Read more

Malignant stem cells may explain why some breast cancers develop and recur

Abnormalities in these cells may indicate the earliest mutations in breast cancers, an OHSU Knight Cancer Institute study found

PORTLAND, Ore. — Mutations that are found in stem cells could be causing some breast cancers to develop and may be the reason the disease recurs. These abnormal cells are likely controlling cell functions in the tumor and, given they are not targeted by chemotherapy and radiation, they enable the disease to recur.

Read more

Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients

PHILADELPHIA — The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed.

Read more

New clinical trial to test novel approach to treat triple-negative breast cancer

Experimental drug may help reprogram tumor cells to respond to hormone therapy

Baltimore, MD — A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women. The study will help researchers determine if an experimental drug, entinostat, can reprogram tumor cells to express a protein called an estrogen receptor to make them sensitive to hormone therapy.

Read more

Breast cancer: A new treatment avenue identified

Montreal, May 17, 2011 - Researchers at the CHUM Research Centre (CRCHUM) and the Peter MacCallum Cancer Centre in Australia have identified a new avenue for treating breast cancer.

In 20 to 30% of breast cancer patients, the over-expression of a particular protein (human epidermal growth factor-2) is the main cause of the proliferation of cancer cells. Over the past few years Herceptin® (trastuzumab) has become the standard treatment for this kind of cancer. While it is known that it blocks the activity of this protein, its exact mechanism of action has remained a mystery.

Read more

New ‘nanodrug’ breaks down barriers to attack breast cancer cells from the inside out

Unlike other drugs that target cancer cells from the outside with minimal effect, this “transport vehicle” carries multiple drugs that spare healthy cells, accumulate in tumor cells and strike cancer-specific molecular targets inside

Read more

« Previous Page — Next Page »